TRIM32抗体

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: Lovo cells, Primary antibody: P07686(TRIM32 Antibody) at dilution 1/200, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 30 minutes    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human cervical cancer tissue using P07686(TRIM32 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colon cancer tissue using P07686(TRIM32 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

The TRIM32 antibody is a research tool used to detect TRIM32 (Tripartite Motif-containing protein 32), a member of the TRIM protein family characterized by RING, B-box, and coiled-coil domains. TRIM32 functions as an E3 ubiquitin ligase, mediating protein ubiquitination and degradation via the proteasome. It plays roles in diverse cellular processes, including cell cycle regulation, differentiation, autophagy, and antiviral responses. TRIM32 is implicated in human diseases: mutations in its gene cause limb-girdle muscular dystrophy type 2H (LGMD2H) and Bardet-Biedl syndrome, while dysregulated expression is linked to cancers, neurodegenerative disorders, and immune pathologies. In cancer, TRIM32 exhibits dual roles, acting as an oncogene (e.g., promoting tumor growth in liver or lung cancer) or tumor suppressor (e.g., inhibiting metastasis in breast cancer), depending on cellular context. Its involvement in muscle atrophy and neural degeneration highlights its regulatory importance in tissue homeostasis.

TRIM32 antibodies are essential for studying its expression, localization, and interactions in experimental models. They enable techniques like Western blotting, immunofluorescence, and co-immunoprecipitation. Specificity validation is critical, as TRIM32 shares structural homology with other TRIM proteins. Research using these antibodies has uncovered TRIM32 substrates, such as c-Myc, dysbindin, and NHL repeat proteins, shedding light on its disease mechanisms. However, inconsistencies in reported functions across studies underscore the need for rigorous antibody characterization. TRIM32 remains a focus for therapeutic targeting, particularly in muscle-wasting disorders and cancers, emphasizing the antibody's role in advancing biomedical research.